Private equity firm pays Covidien $280 million for speciality chemicals arm
This article was originally published in Scrip
Executive Summary
Covidien is to sell its speciality chemicals business to private equity firm New Mountain Capital for $280 million in cash. The healthcare products firm says it wants to streamline its activities and focus on faster growing, higher margin businesses.